BMRN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BMRN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2025-03-23), Biomarin Pharmaceutical's 6-1 Month Momentum % is -3.45%.
The industry rank for Biomarin Pharmaceutical's 6-1 Month Momentum % or its related term are showing as below:
For the Biotechnology subindustry, Biomarin Pharmaceutical's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Biomarin Pharmaceutical's 6-1 Month Momentum % falls into.
6-1 Month Momentum % is calculated as following:
6-1 Month Momentum % | = | ( Price 1-month ago | / | Price 6-month ago | - 1 ) | * | 100 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomarin Pharmaceutical (NAS:BMRN) 6-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Thank you for viewing the detailed overview of Biomarin Pharmaceutical's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Erin Burkhart | officer: GVP, Chief Accounting Officer | C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901 |
Charles Greg Guyer | officer: EVP, Chief Technical Officer | C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901 |
Brian Mueller | officer: EVP, Chief Financial Officer | C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949 |
George Eric Davis | officer: VP, General Counsel | C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949 |
Jean Jacques Bienaime | director, officer: Chief Executive Officer | 925 PAGE MILL ROAD, PALO ALTO CA 94304 |
Jeffrey Robert Ajer | officer: EVP, Chief Commercial Officer | C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949 |
Henry J Fuchs | officer: Chief Medical Officer | C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949 |
Mark J Alles | director | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Elizabeth M Anderson | director | 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807 |
Maykin Ho | director | C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
V Bryan Lawlis | director | |
Richard A Meier | director | C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025 |
Dennis Slamon | director | 770 LINDARO STREET, SAN RAFAEL CA 94901 |
Michael G Grey | director | C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121 |
Pyott David E I | director | C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612 |
From GuruFocus
By PRNewswire • 02-24-2025
By GuruFocus News • 02-25-2025
By PRNewswire • 11-06-2024
By GuruFocus News • 02-20-2025
By PRNewswire • 10-16-2024
By GuruFocus Research • 09-30-2024
By PRNewswire • 02-19-2025
By PRNewswire • 09-04-2024
By PRNewswire • 10-29-2024
By PRNewswire • 01-13-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.